Fragment-based lead discovery and design.
Fragment-based lead discovery and design has and continues to show increasing promise in drug discovery. In this article, the current state of the art in terms of hot-spot characterization, fragment screening techniques, and fragment-based design is discussed. Three overall fragment-based lead generation strategies are explored and involve the chemical biology characterization of biological targets via fragment screening, fragment screening as a complementary approach to high-throughput screening of drug-like compounds, and direct fragment-based drug discovery, respectively. The evolution and development of fragment libraries is described. With an emphasis on computational approaches and the strategies applied at AstraZeneca, the review illustrates how integration of data from one regime can inform the design of experiments in the other, ultimately leading to the discovery of high quality chemical matter.
Infection Innovative Medicines Unit, AstraZeneca, R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
Diane
D
Joseph-McCarthy
Arthur J
AJ
Campbell
Gunther
G
Kern
Demetri
D
Moustakas
D000818:Animals; D018360:Crystallography, X-Ray / Q000379:methods; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D011506:Proteins / Q000378:metabolism; D054852:Small Molecule Libraries / Q000737:chemistry* / Q000494:pharmacology*; D020349:Surface Plasmon Resonance / Q000379:methods
D011506:Proteins; D054852:Small Molecule Libraries